|
|
Article: Northwest Biotherapeutics Signs Synteract for Management of Its DCVax(R)-Brain Cancer Phase II Clinical Trial.
- Article from:
- PR Newswire
- Article date:
- August 15, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Company Completes Key Step to Initiate Phase II Clinical Trial in Patients With Glioblastoma multiforme, the Most Lethal Form of Brain Cancer
BOTHELL, Wash., Aug. 15 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (BULLETIN BOARD: NWBT) announced today that it has taken a key step in initiating its Phase II clinical trial to evaluate DCVax(R)-Brain in patients with Glioblastoma multiforme, by awarding the clinical trial management contract to Synteract (Carlsbad, CA). Synteract will perform full service management of the clinical trial, which is designed and powered as a pivotal trial. DCVax(R)-Brain is a personalized therapeutic cancer vaccine ...